Clovis Oncology Inc  

(Public, NASDAQ:CLVS)   Watch this stock  
86.18
+3.26 (3.93%)
Real-time:   2:04PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 81.94 - 86.78
52 week 35.33 - 102.28
Open 83.52
Vol / Avg. 326,809.00/651,443.00
Mkt cap 3.17B
P/E     -
Div/yield     -
EPS -5.67
Shares 37.59M
Beta 2.03
Inst. own 93%
Aug 6, 2015
Q2 2015 Clovis Oncology Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 6, 2015
Q2 2015 Clovis Oncology Inc Earnings Release - 4:00PM EDT - Add to calendar
May 31, 2015
Clovis Oncology ASCO Investor Event - Webcast
May 6, 2015
Q1 2015 Clovis Oncology Inc Earnings Call - Webcast
May 6, 2015
Q1 2015 Clovis Oncology Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -1174.54%
Operating margin - -1163.00%
EBITD margin - -1062.21%
Return on average assets -33.98% -22.29%
Return on average equity -86.70% -38.58%
Employees 136 -
CDP Score - -

Address

2525 28th St Unit 100
BOULDER, CO 80301-1255
United States - Map
+1-303-6255000 (Phone)
+1-303-2450360 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Clovis Oncology, Inc. (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase (PARP), is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.

Officers and directors

M. James Barrett Ph.D. Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Patrick J. Mahaffy President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Erle T. Mast Chief Financial Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Andrew R. Allen M.D., Ph.D. Executive Vice President - Clinical and Pre-Clinical Development, Chief Medical Officer
Age: 48
Bio & Compensation  - Reuters
Gillian C. Ivers-Read Executive Vice President - Technical Operations, Chief Regulatory Officer
Age: 61
Bio & Compensation  - Reuters
Steven L. Hoerter Senior Vice President - Commercial
Age: 44
Bio & Compensation  - Reuters
Brian G. Atwood Independent Director
Age: 62
Bio & Compensation  - Reuters
James C. Blair Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters
Keith T. Flaherty M.D. Independent Director
Age: 44
Bio & Compensation  - Reuters
Ginger L. Graham Independent Director
Age: 59
Bio & Compensation  - Reuters